Novavax Gets Aggressive With Its Respiratory Syncytial Virus Vaccine
This article was originally published in Scrip
Executive Summary
The prospect of a prophylactic vaccine against respiratory syncytial virus (RSV) has come a step closer with the lead product candidate, Novovax Inc.'s RSV F Vaccine, meeting its major endpoints in a Phase II trial in older adults.
You may also be interested in...
Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?
Case Studies: How Three Public Companies Financed R&D In A Tough Market
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.
Novartis Close To EU Approval For Zolgensma At Last
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
Need a specific report? 1000+ reports available
Buy Reports